Growing research and development of targeted anticancer drugs in China

Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 71, 209, 10.3322/caac.21660 Gamboa, 2020, Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine, CA Cancer J Clin, 70, 200, 10.3322/caac.21605 Grothey, 2021, Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines, Ann Oncol, 32, 959, 10.1016/j.annonc.2021.03.206 Hanna, 2021, Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update, J Clin Oncol, 39, 1040, 10.1200/JCO.20.03570 Bejarano, 2021, Therapeutic targeting of the tumor microenvironment, Cancer Discov, 11, 933, 10.1158/2159-8290.CD-20-1808 Picco, 2021, Werner helicase is a synthetic-lethal vulnerability in mismatch repair-deficient colorectal cancer refractory to targeted therapies, chemotherapy, and immunotherapy, Cancer Discov, 11, 1923, 10.1158/2159-8290.CD-20-1508 Siegel, 2022, Cancer statistics, 2022, CA Cancer J Clin, 72, 7, 10.3322/caac.21708 Zeng, 2018, Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries, Lancet Glob Health, 6, e555, 10.1016/S2214-109X(18)30127-X Li, 2022, Evolution of innovative drug R&D in China, Nat Rev Drug Discov, 21, 553, 10.1038/d41573-022-00058-6 Li, 2019, Changes in clinical trials in mainland China over the decade 2009-18: a systematic review, Lancet Oncol, 20, 619, 10.1016/S1470-2045(19)30491-7 Wu, 2020, Clinical development of immuno-oncology in China, Lancet Oncol, 8, 1013, 10.1016/S1470-2045(20)30329-6 Huang, 2022, Availability and affordability of oncology drugs in 2012-2021 in China and the United States, Front in Oncol, 12 China Food and Drug Administration. Registration and Information Disclosure Platform for Clinical Trials [EB/OL]. [2021/12/3]. http://www.chinadrugtrials.org.cn/. Huang, 2020, Progress on clinical trials of cancer drugs in China, 2019, Zhonghua Zhong Liu Za Zhi, 42, 127 Wu, 2021, Progress on clinical trials of cancer drugs in China, 2020, Zhonghua Zhong Liu Za Zhi, 43, 218 Huang, 2021, Advances on anticancer new drugs in China and the United States in 2020: from ongoing trial to drug approval, J Natl Cancer Cent, 1, 147, 10.1016/j.jncc.2021.08.002 Zhao, 2019, Challenges in anticancer drug R&D in China, Lancet Oncol, 20, 183, 10.1016/S1470-2045(18)30865-9 Zhang, 2021, Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China, J Hematol Oncol, 14, 124, 10.1186/s13045-021-01126-x Central People's Government of the People's Republic of China. Opinions of the State Council on Reforming the Review and Approval System for Drugs and Medical Devices[EB/OL]. 2015. Li, 2021, Characteristics of expedited programmes for cancer drug approval in China, Nat Rev Drug Discov, 20, 416, 10.1038/d41573-021-00080-0 Ginsburg, 2018, Precision medicine: from science to value, Health Aff (Millwood), 37, 694, 10.1377/hlthaff.2017.1624 Huang, 2022, Accelerating the integration of China into the global development of innovative anticancer drugs: Where are we going?, Lancet Oncol. Lancet Oncol., 23, e515, 10.1016/S1470-2045(22)00483-1 Li, 2021, Institutional framework for the management of human genetic resources in China, Hum Gene Ther, 32, 1495, 10.1089/hum.2021.096 Wan, 2022, Sociotechnical safeguards for genomic data privacy, Nat Rev Genet, 23, 429, 10.1038/s41576-022-00455-y Chaturvedi, 2012, Harmonizing policy on human genetic resources and benefit sharing, Nat Biotechnol, 30, 1169, 10.1038/nbt.2441 Chinese Association of Enterprises with Foreign Investment. The third report on building pharmaceutical innovation ecosystem in China: promoting synchronous r&d, registration and evaluation of innovative drugs. http://www.rdpac.org/index.php?r=site%2Fresource (accessed June 11, 2022). Miller, 2019, Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices, BMJ, 366, l4217, 10.1136/bmj.l4217 Kim, 2021, Improving data sharing to increase the efficiency of antibiotic R&D, Nat Rev Drug Discov, 20, 1, 10.1038/d41573-020-00185-y